{"analyses":[{"ciLowerLimit":"0.11","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.69","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Hazard Ratio (HR)","paramValue":"0.28"}],"classes":[{"categories":[{"measurements":[{"comment":"NA = Not reached due to insufficient number of events","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"NA = Not reached due to insufficient number of events","groupId":"OG001","lowerLimit":"12.8","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"110"}],"units":"Participants"}],"description":"Overall survival was defined as the interval from randomization to death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Idelalisib 150 mg tablet administered orally twice daily plus rituximab (8 intravenous doses through Week 20: Day 1: 375 mg/m\\^2, and 500 mg/m\\^2 thereafter)","id":"OG000","title":"Idelalisib + Rituximab"},{"description":"Placebo to match idelalisib administered orally twice daily plus rituximab (8 intravenous doses through Week 20: Day 1: 375 mg/m\\^2, and 500 mg/m\\^2 thereafter)","id":"OG001","title":"Placebo + Rituximab"}],"paramType":"MEDIAN","populationDescription":"ITT Analysis Set: randomized participants with treatment group designated according to initial randomization.","reportingStatus":"POSTED","timeFrame":"Up to 17 months","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}